JP2013500986A5 - - Google Patents

Download PDF

Info

Publication number
JP2013500986A5
JP2013500986A5 JP2012523043A JP2012523043A JP2013500986A5 JP 2013500986 A5 JP2013500986 A5 JP 2013500986A5 JP 2012523043 A JP2012523043 A JP 2012523043A JP 2012523043 A JP2012523043 A JP 2012523043A JP 2013500986 A5 JP2013500986 A5 JP 2013500986A5
Authority
JP
Japan
Prior art keywords
compound according
group
compound
deleted
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012523043A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013500986A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/043719 external-priority patent/WO2011014661A2/en
Publication of JP2013500986A publication Critical patent/JP2013500986A/ja
Publication of JP2013500986A5 publication Critical patent/JP2013500986A5/ja
Pending legal-status Critical Current

Links

JP2012523043A 2009-07-29 2010-07-29 肝臓x受容体アゴニスト Pending JP2013500986A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22938609P 2009-07-29 2009-07-29
US61/229,386 2009-07-29
PCT/US2010/043719 WO2011014661A2 (en) 2009-07-29 2010-07-29 Liver x receptor agonists

Publications (2)

Publication Number Publication Date
JP2013500986A JP2013500986A (ja) 2013-01-10
JP2013500986A5 true JP2013500986A5 (US07585860-20090908-C00112.png) 2013-08-15

Family

ID=43529941

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012523043A Pending JP2013500986A (ja) 2009-07-29 2010-07-29 肝臓x受容体アゴニスト

Country Status (6)

Country Link
US (1) US8829213B2 (US07585860-20090908-C00112.png)
EP (1) EP2459581A4 (US07585860-20090908-C00112.png)
JP (1) JP2013500986A (US07585860-20090908-C00112.png)
CN (1) CN102482315A (US07585860-20090908-C00112.png)
CA (1) CA2769203A1 (US07585860-20090908-C00112.png)
WO (1) WO2011014661A2 (US07585860-20090908-C00112.png)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2665571C2 (ru) 2011-09-08 2018-08-31 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, композиции и их применения
CN103360453B (zh) * 2012-04-04 2015-10-07 浙江大学 四环三萜类化合物的制备和抗衰老应用
CN103360456B (zh) * 2012-04-04 2015-07-29 浙江大学 三萜类化合物及制备和应用
EP2759295A1 (en) 2013-01-29 2014-07-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Foam cell specific Liver X Receptor (LXR) alpha agonist, SIRT1 inhibitors as well as p300 inhibitors as pharmaceutically active agents
RS58166B1 (sr) 2013-03-13 2019-03-29 Sage Therapeutics Inc Neuroaktivni steroidi i postupci za njihovu upotrebu
CN104072564B (zh) * 2013-03-28 2016-08-17 广州市赛普特医药科技股份有限公司 2β,3α,5α-三羟基-雄甾-6-酮及其制备方法与用途
JP6320861B2 (ja) * 2013-10-16 2018-05-09 株式会社ファンケル コレステロール吸収阻害剤
AU2015204572B2 (en) 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
TWI686401B (zh) 2014-11-19 2020-03-01 英商Nzp英國有限公司 化合物(三)
MX2017006567A (es) 2014-11-19 2018-01-26 Nzp Uk Ltd Esteroides 6.alfa.-alquil-6,7-diona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).
CA2968309A1 (en) 2014-11-19 2016-05-26 NZP UK Limited 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
DK3221332T3 (da) 2014-11-19 2019-07-29 Nzp Uk Ltd Fremstilling af steroide fxr-modulatorer
CN113501855A (zh) 2015-07-06 2021-10-15 萨奇治疗股份有限公司 氧甾醇及其使用方法
AU2016289965B2 (en) 2015-07-06 2021-09-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
RU2744267C2 (ru) 2015-07-06 2021-03-04 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
WO2017115319A2 (en) * 2015-12-30 2017-07-06 Consejo Nacional De Investigaciones Científicas Y Técnicas (Conicet) Use of brassinosteroid analogs for the treatment of dermal disorders by selectively modulating liver x receptors (lxr) and dermal disease treatment by brassinosteroid analogs acting as selective liver x receptor (lxr) modulators
JP7025022B2 (ja) 2016-01-11 2022-02-24 ザ ロックフェラー ユニバーシティー 骨髄系由来抑制細胞関連障害の治療のための方法
PT3436022T (pt) 2016-04-01 2022-07-04 Sage Therapeutics Inc Oxisteróis e métodos de utilização dos mesmos
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN106188205B (zh) * 2016-05-06 2017-08-25 深圳以诺生物制药有限公司 一种罗汉果醇衍生物单体及其组合物的用途
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
IT201600068742A1 (it) * 2016-07-01 2018-01-01 Bar Pharmaceuticals Soc A Responsabilita Limitata Derivati dell'acido iodesossicolico e loro uso
MA45598B1 (fr) 2016-07-07 2021-09-30 Sage Therapeutics Inc Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
AU2017337121B2 (en) 2016-09-30 2022-01-27 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as NMDA modulators
EP4105223A1 (en) 2016-10-18 2022-12-21 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
IL266093B2 (en) 2016-10-18 2024-02-01 Sage Therapeutics Inc Oxysterols and methods of using them
US11214536B2 (en) 2017-11-21 2022-01-04 Inspirna, Inc. Polymorphs and uses thereof
JP2022514257A (ja) * 2018-12-13 2022-02-10 アイノス,インコーポレイテッド ドライアイ疾患の治療のための局所点眼製剤におけるlxrアゴニスト
WO2021119397A1 (en) 2019-12-13 2021-06-17 Rgenix, Inc. Metal salts and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698853A (en) 1951-08-11 1955-01-04 Monsanto Chemicals Oxidation of steroids
FR1482102A (fr) 1966-03-31 1967-05-26 Centre Nat Rech Scient Nouveaux dérivés de stéroïdes et procédé de préparation
US3784598A (en) 1972-01-20 1974-01-08 Ciba Geigy Corp Process for the conversion of a 3-hydroxy-5,6-oxido group of a steroid into a delta4-3-oxo group
JPS4976857A (US07585860-20090908-C00112.png) 1972-12-06 1974-07-24
US3963765A (en) 1973-04-01 1976-06-15 Yehuda Mazur Preparation of derivatives of cholesterol
US3887545A (en) 1973-11-12 1975-06-03 Hoffmann La Roche Synthesis of 1{60 -hydroxylated cholesterol derivatives
US4006172A (en) 1976-04-26 1977-02-01 The Upjohn Company Process for 7-keto-Δ5 -steroids
US4125544A (en) 1977-06-09 1978-11-14 G. D. Searle 20/22/23/24-Oxa-7-oxocholesterols and esters thereof
US4193930A (en) 1977-08-29 1980-03-18 G. D. Searle & Co. 25-Alkyl-3β-hydroxycholest-5-en-7-ones and esters thereof
JPS5448751A (en) 1977-08-29 1979-04-17 Searle & Co 255alkylcholesterol derivative
JPS563000A (en) 1979-06-20 1981-01-13 Green Cross Corp:The Water-soluble cholesterol derivative
US4639420A (en) 1984-11-21 1987-01-27 Schaffner Carl P Method for the immunoanalysis of cholesterol epoxides
US4917998A (en) * 1986-05-06 1990-04-17 Epitope, Inc. Method of detecting AIDS virus infection
IT1212141B (it) 1987-06-03 1989-11-08 So Ri Far S R L Composizioni farmaceutiche per la prevenzione e terapia della calcolosi delle vie biliari e della dispepsia biliare.
WO1989003212A1 (en) 1987-10-13 1989-04-20 Pfizer Inc. 3,5-dihydroxy-6,8-nonadienoic acids and derivatives as hypocholesterolemic agents
US5562910A (en) 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5424463A (en) 1990-08-29 1995-06-13 Humanetics Corporation Δ5-androstenes useful for promoting weight maintenance or weight loss and treatment process
JPH0749438B2 (ja) 1990-10-31 1995-05-31 東京田辺製薬株式会社 タウリン抱合型胆汁酸の精製方法
IL105050A0 (en) 1992-03-27 1993-07-08 Lilly Co Eli Steroid derivatives
IT1255241B (it) 1992-07-22 1995-10-20 Simos Contos Derivato di acido biliare e suo uso in terapia
IT1255486B (it) 1992-08-04 1995-11-06 Erregierre Ind Chim Processo per preparare gli acidi biliari coniugati con la taurina
US5482935A (en) 1993-01-05 1996-01-09 American Home Product Corporation Anti-atherosclerotic use of 17 alpha-dihydroequilin
TW289757B (US07585860-20090908-C00112.png) 1993-05-08 1996-11-01 Hoechst Ag
IT1270853B (it) 1993-05-20 1997-05-13 Sanofi Elf Procedimento per la preparazione di derivati taurocolanici
CN1055929C (zh) 1993-09-20 2000-08-30 中国科学院上海有机化学研究所 三氟甲基甾体化合物及其制备方法
IT1274000B (it) 1994-04-06 1997-07-14 Alfa Wassermann Spa Derivati di acidi biliari utili nella terapia della calcolosi biliare da colesterolo e nelle patologie indotte da colestasi
AU688513B2 (en) 1994-05-19 1998-03-12 Merck & Co., Inc. Oxidation of steroids having allylic groups
US5583239A (en) 1995-05-30 1996-12-10 Lehigh University Antimicrobial sterol conjugates
BR9806989A (pt) 1997-01-24 2000-03-14 Univ California Processo para tratar a epiderme ou membrana da mucosa de um indivìduo mamìfero.
US6060465A (en) 1997-02-06 2000-05-09 Miljkovic; Dusan Bile acids and their derivatives as glycoregulatory agents
US7012069B2 (en) 2001-05-03 2006-03-14 Arch Development Corporation Liver X receptor agonists
AU2389100A (en) 1998-12-23 2000-07-12 Glaxo Group Limited Assays for ligands for nuclear receptors
AU2409600A (en) 1999-01-07 2000-07-24 Tularik Inc. Fxr receptor-mediated modulation of cholesterol metabolism
AU775630B2 (en) 1999-04-30 2004-08-05 Arch Development Corporation Steroid derivatives
JP2002030097A (ja) * 2000-07-11 2002-01-29 Kyorin Pharmaceut Co Ltd ステロイド誘導体の製造方法
JP2002030096A (ja) 2000-07-11 2002-01-29 Kyorin Pharmaceut Co Ltd 神経細胞突起再生剤及びその製造方法
DE10105041A1 (de) 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptide und Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten
CN1498222A (zh) 2001-02-08 2004-05-19 芝加哥大学 类固醇衍生物
US7078396B2 (en) 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
JP2005508368A (ja) 2001-11-08 2005-03-31 ザ ユニバーシティー オブ シカゴ 高コレステロール濃度に関連した疾患の治療方法
WO2003086303A2 (en) 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
US20070032464A1 (en) * 2004-10-08 2007-02-08 Shutsung Liao Methods of treating cancers

Similar Documents

Publication Publication Date Title
JP2013500986A5 (US07585860-20090908-C00112.png)
JP2013508279A5 (US07585860-20090908-C00112.png)
JP2015505296A5 (US07585860-20090908-C00112.png)
JP2013537203A5 (US07585860-20090908-C00112.png)
JP2012525393A5 (US07585860-20090908-C00112.png)
JP2010521516A5 (US07585860-20090908-C00112.png)
TWI598098B (zh) 脂質異常症治療劑
RU2016103139A (ru) Новые композиции для предупреждения и/или лечения лизосомных болезней накопления
JP2020507589A5 (US07585860-20090908-C00112.png)
JP2013518107A5 (US07585860-20090908-C00112.png)
JP2013512277A5 (US07585860-20090908-C00112.png)
JP2009263394A5 (US07585860-20090908-C00112.png)
JP2011006480A5 (US07585860-20090908-C00112.png)
JP2009507909A5 (US07585860-20090908-C00112.png)
JP2008533007A5 (US07585860-20090908-C00112.png)
JP2009084270A5 (US07585860-20090908-C00112.png)
JP2011504903A5 (US07585860-20090908-C00112.png)
JP2015508092A5 (US07585860-20090908-C00112.png)
RU2007102576A (ru) Новые индаэолкарбоксамиды и их применение
JP2011246469A5 (US07585860-20090908-C00112.png)
JP2014505107A5 (US07585860-20090908-C00112.png)
JP2013506674A5 (US07585860-20090908-C00112.png)
JP2015521156A5 (US07585860-20090908-C00112.png)
RU2007118691A (ru) Применение 4-трифторметилфениламида (z)-2-циано-3-гидрокси-бут-2-еновой кислоты для лечения воспалительных заболеваний кишечника
JP2013545823A5 (US07585860-20090908-C00112.png)